{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-239362","form_type":"8-K","ticker":"KLRA","cik":"0002096997","company_name":"Kailera Therapeutics, Inc.","filed_at":"2026-05-26T20:18:46+00:00","discovered_at":"2026-05-26T20:20:00.443765+00:00","generated_at":"2026-05-26T20:21:20.754452+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"confidence":"high","headline":"Kailera Q1 net loss $78.9M; advances obesity pipeline with Phase 3 start and positive data","bullets":["Net loss of $78.9M in Q1 2026 vs $18.0M in Q1 2025; R&D expenses rose to $70.9M from $10.1M.","Cash $581.9M plus IPO proceeds of $718.8M expected to fund operations into mid-2028.","Initiated global Phase 3 KaiNETIC program for ribupatide injection; data expected 2028.","Positive Phase 2 oral ribupatide data: mean weight loss up to 12.1% at week 26; Phase 3 trials planned for early 2027.","Positive Phase 1 data for KAI-4729 tri-agonist: up to 16.0% weight loss at 12 weeks; Phase 1 outside China planned 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-239362","json":"https://secwatch.observer/filing/0001193125-26-239362.json","markdown":"https://secwatch.observer/filing/0001193125-26-239362.md","text":"https://secwatch.observer/filing/0001193125-26-239362.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2096997/000119312526239362/0001193125-26-239362-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2096997/000119312526239362/ck0002096997-20260526.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T20:21:20.754452+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}